Michael Hebeisen Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Switzerland
1 protocol

Nathalie Rufer Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Switzerland
1 protocol

Pedro Romero Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
3 protocols

Petra Baumgaertner Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
1 protocol

Daniel E. Speiser
  • Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
  • 1 Author merit

Education

M.D in University of Zürich, Switzerland, 1982

Current position

Associate and Full Professor, respectively, University of Lausanne, Switzerland

Publications (selected)

  1. Robert-Tissot, C. and Speiser, D. E. (2016). Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies. Cancer Discov 6(1): 17-19.

  2. Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P. and Speiser, D. E. (2015). Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112(19): 6140-6145.

  3. Fuertes Marraco, S. A., Soneson, C., Cagnon, L., Gannon, P. O., Allard, M., Abed Maillard, S., Montandon, N., Rufer, N., Waldvogel, S., Delorenzi, M. and Speiser, D. E. (2015). Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile upon yellow fever vaccination. Sci Transl Med 7(282): 282ra248.

  4. Speiser, D. E., Utzschneider, D. T., Oberle, S. G., Munz, C., Romero, P. and Zehn, D. (2014). T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 14(11): 768-774.

  5. Utzschneider, D. T., Legat, A., Fuertes Marraco, S. A., Carrie, L., Luescher, I., Speiser, D. E. and Zehn, D. (2013). T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 14(6): 603-610.

  6. Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O., Zoete, V., Michielin, O., Muehlethaler, K., Speiser, D., Beckmann, J. S., Xenarios, I., Halazonetis, T. D., Jongeneel, C. V., Stevenson, B. J. and Antonarakis, S. E. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44(2): 133-139.

  7. Baitsch, L., Baumgaertner, P., Devevre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., Rufer, N. and Speiser, D. E. (2011). Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest 121(6): 2350-2360.

  8. Speiser, D. E., Lienard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A. M., Cerottini, J. C. and Romero, P. (2005). Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115(3): 739-746.

  9. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M. and Ohashi, P. S. (1997). Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186(5): 645-653.

  10. Speiser, D. E., Stubi, U. and Zinkernagel, R. M. (1992). Extrathymic positive selection of alpha beta T-cell precursors in nude mice. Nature 355(6356): 170-172.

  11. Speiser, D. E., Lees, R. K., Hengartner, H., Zinkernagel, R. M. and MacDonald, H. R. (1989). Positive and negative selection of T cell receptor V beta domains controlled by distinct cell populations in the thymus. J Exp Med 170(6): 2165-2170.

1 Protocol published
Chromium-51 (51Cr) Release Assay to Assess Human T Cells for Functional Avidity and Tumor Cell Recognition
Authors:  Petra Baumgaertner, Daniel E. Speiser, Pedro Romero, Nathalie Rufer and Michael Hebeisen, date: 08/20/2016, view: 7224, Q&A: 0
Cytotoxic CD8+ T cells are able to specifically recognize and kill target cells through specific interaction between their T cell receptors (TCRs) and small immunogenic peptides (antigens) presented by major histocompatibility complex ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.